Fibroblast Growth Factor 23-Mediated Bone Disease.

Area of Science:

• Endocrinology
• Metabolic Bone Disease
• Molecular Biology

Background:

• Fibroblast growth factor 23 (FGF23) is a key hormone controlling phosphate and vitamin D homeostasis.
• Imbalances in FGF23 levels are linked to numerous skeletal pathologies.
• The FGF23-α-Klotho axis is crucial for these metabolic functions.

Purpose of the Study:

• To review the FGF23-α-Klotho signaling pathway.
• To highlight recent advancements in FGF23 regulation and function.
• To describe skeletal disorders stemming from FGF23 dysregulation.

Main Methods:

• Literature review of FGF23 research.
• Analysis of FGF23-α-Klotho pathway mechanisms.
• Synthesis of clinical data on FGF23-related disorders.

Main Results:

• Detailed overview of FGF23 synthesis, secretion, and target organ actions.
• Explanation of the role of α-Klotho as a co-receptor for FGF23.
• Summarization of genetic and acquired conditions associated with FGF23 excess or deficiency.

Conclusions:

• The FGF23-α-Klotho pathway is central to mineral metabolism.
• Understanding FGF23 regulation and signaling is vital for diagnosing and managing skeletal disorders.
• Further research into FGF23 may reveal novel therapeutic targets.